{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:24:19Z","timestamp":1786947859285,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While immune checkpoint inhibitors (ICIs) have revolutionized first-line treatment for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma, outcomes across phase III trials remained heterogeneous. This study aimed to determine the efficacy and safety of ICI plus chemotherapy, and to define a clinically meaningful PD-L1 expression threshold through a meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, and Cochrane for phase III randomized controlled trials (up to November 2025) comparing ICI-chemotherapy combinations against chemotherapy alone in patients with advanced gastric or GEJ adenocarcinoma. The combined hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were calculated using a random-effects model. Safety was assessed through the combined risk ratio (RR) of grade \u22653 adverse events (AEs) and serious adverse events (SAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight trials involving 7,127 patients with previously untreated, HER2-negative, advanced gastric or GEJ adenocarcinoma were included. The pooled analysis showed a significant improvement in OS (HR\u00a0=\u00a00.79) and PFS (HR\u00a0=\u00a00.71) with immunochemotherapy versus chemotherapy alone. Immunochemotherapy was associated with longer median OS (14.4 vs 12.6 months) and PFS (7.3 vs 6.2 months). Treatment benefit increased with higher PD-L1 combined positive score (CPS): OS HRs were 0.90 (CPS &amp;lt; 1), 0.76 (CPS \u2265 1), 0.74 (CPS \u2265 5), and 0.65 (CPS \u2265 10). Combination therapy modestly increased grade \u22653 AEs (RR\u00a0=\u00a01.16) and SAEs (RR\u00a0=\u00a01.54) compared with chemotherapy alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results supported the strategy of first-line immunochemotherapy, which significantly prolongs OS and PFS in advanced gastric and GEJ adenocarcinoma with manageable toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251180445<\/jats:ext-link>\n                      , identifier CRD420251180445.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1866848","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:26:06Z","timestamp":1786944366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy hierarchy and absolute survival benefit of first-line immunotherapy in advanced gastric cancer: a meta-analysis and pooled survival analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Jialun","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnapriya","family":"Thangaretnam","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Obaidul","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Tang","sequence":"additional","affiliation":[{"name":"American Heritage Schools, Broward Campus","place":["Plantation, Florida, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Denize","sequence":"additional","affiliation":[{"name":"Doctors Charter School of Miami Shores","place":["Miami shores, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Bhat","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoumin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunfa","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"El-Rifai","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]},{"name":"Department of Veterans Affairs, Miami Healthcare System","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30354-3","article-title":"Gastric cancer","volume":"388","author":"Van Cutsem","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221118874","article-title":"European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions","volume":"14","author":"Pavlakis","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac014","article-title":"Metastatic colorectal cancer outcomes by age among ARCAD first- and second-line clinical trials","volume":"6","author":"McCleary","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.2024.28463","article-title":"First-line sugemalimab plus chemotherapy for advanced gastric cancer: The GEMSTONE-303 randomized clinical trial","volume":"333","author":"Zhang","year":"2025","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003094","article-title":"Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer","volume":"137","author":"Jiang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-023-01232-y","article-title":"The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation","volume":"30","author":"Liu","year":"2023","journal-title":"Cell Death Differ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1009254","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials","volume":"13","author":"Gu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249330","article-title":"Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy","volume":"14","author":"Razaghi","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.20900\/immunometab20220007","article-title":"Effects of PD-1 signaling on immunometabolic reprogramming","volume":"4","author":"Boussiotis","year":"2022","journal-title":"Immunometabolism"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001633","article-title":"PD-L1 expression in endocervical adenocarcinoma: Correlation with patterns of tumor invasion, CD8+ tumor-infiltrating lymphocytes, and clinical outcomes","volume":"45","author":"Rivera-Colon","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-01102-z","article-title":"Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer","volume":"30","author":"Yang","year":"2023","journal-title":"Cell Death Differ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials","volume":"16","author":"Pu","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101251","article-title":"Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response","volume":"4","author":"Kim","year":"2023","journal-title":"Cell Rep Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100194","article-title":"Profiling of immune features to predict immunotherapy efficacy","volume":"3","author":"Ye","year":"2022","journal-title":"Innovation (Camb)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001191","article-title":"Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.12.017","article-title":"KBTBD8\/RRP15 as a potential novel therapeutic target associates with lenvatinib-inhibited progression in hepatocellular carcinoma both in vitro and in vivo","volume":"76","author":"Zhao","year":"2025","journal-title":"J Adv Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1259-6","article-title":"Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update","volume":"23","author":"Nagai","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"31581","DOI":"10.1038\/s41598-025-16993-4","article-title":"Cox proportional hazards model with Bayesian neural network for survival prediction","volume":"15","author":"Faghiri","year":"2025","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1674","article-title":"Use of multiple covariates in assessing treatment-effect modifiers: a methodological review of individual participant data meta-analyses","volume":"15","author":"Godolphin","year":"2024","journal-title":"Res Synth Methods"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1866848\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:26:07Z","timestamp":1786944367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1866848\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1866848"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1866848","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1866848"}}